Hirakata

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Diabetic eye disease1 trial
• High blood pressure1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 12 trials
• Phase 32 trials

Status

• Completed5 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Recruiting

  Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

  NCT07604571· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  NCT07570979· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Special Drug Use Surveillance of Entresto Tablets (Hypertension)

  NCT05976230· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection

  NCT05526729· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

  NCT01828112· Phase 3· Novartis Pharmaceuticals· Source